2019
DOI: 10.1016/j.jns.2019.08.001
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and tolerability of perampanel as an adjunct therapy in refractory epilepsy from real-world experience

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

1
3
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(4 citation statements)
references
References 5 publications
1
3
0
Order By: Relevance
“…Similar to other studies, among the concomitant ASMs, the majority of patients took LEV and VPA (26,30). In the present study, VPA was the most common concomitant ASM (64.3%), followed by LEV (55.4%).…”
Section: Discussionsupporting
confidence: 89%
“…Similar to other studies, among the concomitant ASMs, the majority of patients took LEV and VPA (26,30). In the present study, VPA was the most common concomitant ASM (64.3%), followed by LEV (55.4%).…”
Section: Discussionsupporting
confidence: 89%
“…15 Local data for perampanel in Hong Kong were previously reported in a retrospective study by Chang et al The reported 50% responder rate was 32.1%, and seizure freedom rate 13.2%, with a treatment-emergent adverse event (TEAE) withdrawal rate 28.3%. 16…”
Section: Introductionmentioning
confidence: 99%
“…The reported 50% responder rate was 32.1%, and seizure freedom rate 13.2%, with a treatment‐emergent adverse event (TEAE) withdrawal rate 28.3%. 16 …”
Section: Introductionmentioning
confidence: 99%
“… 4 5 6 7 However, these studies did not ensure their efficacy in real-world circumstances due to their inflexible designs. Accordingly, several real-world observational studies 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 have been conducted in various countries, but studies with sufficiently long observation periods are still lacking.…”
Section: Introductionmentioning
confidence: 99%